bluebird bio (LSE:0HOH) - Prezzo delle azioni, notizie e analisi

0HOH Panoramica delle azioni

bluebird bio, Inc. è una società di biotecnologie che ricerca, sviluppa e commercializza terapie geniche per la cura di gravi malattie genetiche negli Stati Uniti. Maggiori dettagli

0HOH analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Premi

Negoziato a 95.8% al di sotto della nostra stima del suo valore equo

Si prevede che i ricavi cresceranno 41.53% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Ha meno di 1 anno di pista di cassa

Patrimonio netto negativo

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

+ 2 più rischi

bluebird bio, Inc. Concorrenti

Arecor Therapeutics

AIM:AREC

UK£28.9m

Avacta Group

AIM:AVCT

UK£168.3m

Tissue Regenix Group

AIM:TRX

UK£41.0m

BSF Enterprise

LSE:BSFA

UK£3.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per bluebird bio
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.38
Massimo di 52 settimane	US$5.53
Minimo di 52 settimane	US$0.29
Beta	0.80
1Variazione di 1 mese	-24.08%
Variazione a 3 mesi	-37.96%
Variazione di 1 anno	-90.26%
3Variazione a 3 anni	-96.33%
Variazione a 5 anni	-99.50%
Variazione dall'IPO	-99.81%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	0HOH	GB Biotechs	GB Mercato
7D	25.7%	1.5%	1.7%
1Y	-90.3%	-16.3%	8.4%

Ritorno vs Industria: 0HOH ha avuto una performance inferiore rispetto al UK Biotechs che ha registrato un rendimento -16.3 % nell'ultimo anno.

Rendimento vs Mercato: 0HOH ha avuto una performance inferiore al mercato UK che ha registrato un rendimento 8.4 % nell'ultimo anno.

Volatilità dei prezzi

Is 0HOH's price volatile compared to industry and market?
0HOH volatility
0HOH Average Weekly Movement	13.0%
Biotechs Industry Average Movement	9.0%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Prezzo delle azioni stabile: Il prezzo delle azioni di 0HOH è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 13% ) di 0HOH è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni UK.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc. è una società di biotecnologie che ricerca, sviluppa e commercializza negli Stati Uniti terapie geniche per la cura di gravi malattie genetiche. I prodotti candidati dell'azienda per le malattie genetiche gravi includono ZYNTEGLO (betibeglogene autotemcel) per il trattamento della ß-talassemia trasfusione-dipendente; lovotibeglogene autotemcel per il trattamento della malattia a cellule falciformi (SCD); e SKYSONA (elivaldogene autotemcel) per il trattamento dell'adrenoleucodistrofia cerebrale. I suoi programmi di sviluppo clinico includono HGB-205, HGB-206 e HGB-210 per valutare la sicurezza e l'efficacia di lovo-cel nel trattamento di pazienti affetti da SCD; e HGB-204, HGB-205, HGB-207 e HGB-212 per valutare la sicurezza e l'efficacia di beti-cel nel trattamento di pazienti affetti da ß-talassemia.

bluebird bio, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di bluebird bio con la sua capitalizzazione di mercato?
0HOH statistiche fondamentali
Capitalizzazione di mercato	US$71.94m
Guadagni(TTM)	-US$292.82m
Ricavi(TTM)	US$53.12m

1.4x

Rapporto P/S

-0.2x

Rapporto P/E

0HOH è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
0HOH Conto economico (TTM)
Ricavi	US$53.12m
Costo del fatturato	US$78.78m
Profitto lordo	-US$25.66m
Altre spese	US$267.16m
Guadagni	-US$292.82m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.51
Margine lordo	-48.31%
Margine di profitto netto	-551.25%
Rapporto debito/patrimonio netto	-1,394.4%

Come si è comportato 0HOH nel lungo periodo?

Vedi performance storica e confronto

0HOH Panoramica delle azioni

Premi

Analisi del rischio

bluebird bio, Inc. Concorrenti

AIM:AREC

UK£28.9m

AIM:AVCT

UK£168.3m

AIM:TRX

UK£41.0m

LSE:BSFA

UK£3.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.66 loss in 3Q 2023)

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Now 41% undervalued after recent price drop

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Now 20% undervalued after recent price drop

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold US$78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold US$96k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold US$74k worth of stock

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022